New hope for advanced cancer? first human trial of HS-20122 begins

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females, aged ≥ 18 years. * Subjects with histologically or cytologically confirmed locally advanced or metastatic Solid Tumors * Standard treatment is invalid, unavailable or intolerable. * At least 1 target lesion according to RECIST 1.1. * ECOG PS score: 0-1. * Estimated Life expectancy\> 12 weeks. * Men or women should be using adequate contraceptive measures throughout the study. * Women must have the evidence of non-childbearing potential. * Signed and dated Informed Consent Form. Exclusion Criteria: * Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity * History of other primary malignancies. * Inadequate bone marrow reserve or organ dysfunction. * Evidence of cardiovascular risk. * Subjects with severe or poorly controlled diabetes. * Subjects with severe or poorly controlled hypertension. * Subjects with clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose. * Subjects with severe arteriovenous thrombotic events within 3 months. * Subjects with severe infection within 4 weeks prior to the first dose. * Subjects who have received steroid therapy for more than 30 days . * Presence of known active infectious diseases. * Presence of clinically significant gastrointestinal dysfunction. * Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis ≥ Child-Pugh Grade B. * Moderate to severe pulmonary diseases. * Prior history of significant neurological or mental disorders. * Women who are breastfeeding or pregnant or planned to be pregnant during the study period. * Hypersensitivity to any ingredient of HS-20122. * Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator * Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity * History of other primary malignancies. * Inadequate bone marrow reserve or organ dysfunction. * Evidence of cardiovascular risk. * Subjects with severe or poorly controlled diabetes. * Subjects with severe or poorly controlled hypertension. * Subjects with clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose. * Subjects with severe arteriovenous thrombotic events within 3 months. * Subjects with severe infection within 4 weeks prior to the first dose. * Subjects who have received steroid therapy for more than 30 days . * Presence of known active infectious diseases. * Presence of clinically significant gastrointestinal dysfunction. * Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis ≥ Child-Pugh Grade B. * Moderate to severe pulmonary diseases. * Prior history of significant neurological or mental disorders. * Women who are breastfeeding or pregnant or planned to be pregnant during the study period. * Hypersensitivity to any ingredient of HS-20122. * Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator * Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments